|
〔1〕 SIEGEL R L, MILLER K D, JEMAL A. Cancer Statistics, 2019〔J〕. CA Cancer J Clin,2019,69(1):7-34.
〔2〕 GOGINENI V, MORAND S, STAATS H, et al. Current Ovarian Cancer Maintenance Strategies and Promising New Developments〔J〕. J Cancer,2021,12(1):38-53.
〔3〕 FERRERO A, BORGHESE M, RESTAINO S, et al. Predicting Response to Anthracyclines in Ovarian Cancer〔J〕. Int J Environ Res Public Health,2022,19(7):4260.
〔4〕 RADU M R, PR?魤DATU A, DUIC?魤 F, et al. Ovarian Cancer: Biomarkers and Targeted Therapy〔J〕. Biomedi-cines,2021,9(6):693.
〔5〕 AUGOFF K, HRYNIEWICZ-JANKOWSKA A, TABOLA R, et al. MMP9: A Tough Target for Targeted Therapy for Cancer〔J〕. Cancers (Basel),2022,14(7):1847.
〔6〕 WANG Y, YE Y, LIN J, et al. Genetic Variants in Matrix Metalloproteinase Genes as Disposition Factors for Ovarian Cancer Risk, Survival, and Clinical Outcome〔J〕. Mol Carcinog,2015,54(6):430-439.
〔7〕 MADARIAGA A, GARG S, BRUCE J P, et al. Biomarkers of Outcome to Weekly Paclitaxel in Epithelial Ovarian Cancer〔J〕. Gynecol Oncol,2020,159(2):539-545.
〔8〕 COWDEN DAHL K D, SYMOWICZ J, NING Y, et al. Matrix Metalloproteinase 9 Is a Mediator of Epidermal Growth Factor-Dependent E-Cadherin Loss in Ovarian Carcinoma Cells〔J〕. Cancer Res,2008,68(12):4606-4613.
〔9〕 ZHU X M, SUN W F. Association between Matrix Metalloproteinases Polymorphisms and Ovarian Cancer Risk: A Meta-Analysis and Systematic Review〔J〕. PLoS One,2017,12(9):e0185456.
〔10〕 BEEGHLY-FADIEL A, LU W, SHU X O, et al. MMP9 Polymorphisms and Breast Cancer Risk: A Report from the Shanghai Breast Cancer Genetics Study〔J〕. Breast Cancer Res Treat,2011,126(2):507-513.
〔11〕 WANG K, ZHOU Y, LI G, et al. MMP8 and MMP9 Gene Polymorphisms Were Associated with Breast Cancer Risk in a Chinese Han Population〔J〕. Sci Rep,2018,8(1):13422.
〔12〕 BELOTTI D, PAGANONI P, MANENTI L, et al. Matrix Metalloproteinases (MMP9 and MMP2) Induce the Release of Vascular Endothelial Growth Factor (VEGF) by Ovarian Carcinoma Cells: Implications for Ascites Formation〔J〕. Cancer Res,2003,63(17):5224-5229.
|